Atsushi Amano

3PUBLICATIONS
2CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Solid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Jan 06, 2021
Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.

Yasuo Terauchi, Daisuke Yabe, Hideaki Kaneto

|Apr 16, 2020
Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial.

Yasuo Terauchi, Takahiro Nakama, Robert Spranger

|Feb 20, 2020
Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial.

Hideaki Kaneto, Akane Takami, Robert Spranger

Pageof 1

Frequent Collaborators

2 joint publications

Yasuo Terauchi

1 joint publications

Hirotaka Watada